

# PLOS ONE

## Electromyographic parameters for treating pelvic floor disorders in pregnant and postpartum women: A review protocol --Manuscript Draft--

<b>Manuscript Number:</b>	PONE-D-23-43712
<b>Article Type:</b>	Registered Report Protocol
<b>Full Title:</b>	Electromyographic parameters for treating pelvic floor disorders in pregnant and postpartum women: A review protocol
<b>Short Title:</b>	Electromyographic parameters for treating pelvic floor disorders: A review protocol
<b>Corresponding Author:</b>	ALETHEA CURY RABELO LEITAO, Ms. Federal University of Rio Grande do Norte: Universidade Federal do Rio Grande do Norte Parnamirim, RN BRAZIL
<b>Keywords:</b>	Electromyography, pelvic floor disorders, pregnant, postpartum
<b>Abstract:</b>	Electromyography is a widely used instrument in clinical practice to evaluate and treat pelvic floor disorders in pregnant and postpartum women. The objective of this study is to analyze the scientific evidence on the electromyography parameters used for treating pelvic floor disorders in pregnant women in any gestational week and postpartum women up to 12 months after delivery. A systematic review will be performed in online databases (Scopus, Medline, Pedro, Scielo and Pubmed) of randomized controlled experimental studies and quasi-experimental studies, in English, Portuguese or Spanish, which used electromyography as an intervention for treating pelvic floor disorders in pregnant or post-childbirth women up to 12 months after birth. Risk of bias assessment will be performed using Cochrane group tools. The Rob 2.0 tool will be used for experimental studies and the Robins-I tool for non-experimental studies. The protocol was registered in PROSPERO (nº.433510). The quality of the evidence will be analyzed using the GRADE System Methodological Guide and the systematic review structure will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
<b>Order of Authors:</b>	ALETHEA CURY RABELO LEITAO, Ms. Silvia Oliveira Ribeiro Lira, Dra. Elizabel de Souza Ramalho Viana, Dra.
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
<b>Financial Disclosure</b>  Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the <a href="#">submission guidelines</a> for detailed requirements. View published research articles from <a href="#">PLOS ONE</a> for specific examples.  This statement is required for submission and <b>will appear in the published article</b> if the submission is accepted. Please make sure it is accurate.	NO  The funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Unfunded studies**

Enter: *The author(s) received no specific funding for this work.*

**Funded studies**

Enter a statement with the following details:

- Initials of the authors who received each award
- Grant numbers awarded to each author
- The full name of each funder
- URL of each funder website
- Have or will the sponsors or funders play any role in the study design, data collection (when applicable) and analysis, decision to publish, or preparation of the manuscript?
- **NO** - Include this sentence at the end of your statement: *The funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*
- **YES** - Specify the role(s) played.

\* typeset

**Competing Interests**

Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any [competing interests](#) that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement is **required** for submission and **will appear in the published article** if the submission is accepted. Please make sure it is accurate and that any funding sources listed in your Funding Information later in the submission form are also declared in your Financial Disclosure statement.

View published research articles from [PLOS ONE](#) for specific examples.

The authors have declared that no competing interests exist.

**NO authors have competing interests**

Enter: *The authors have declared that no competing interests exist.*

**Authors with competing interests**

Enter competing interest details beginning with this statement:

*I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]*

\* typeset

**Ethics Statement**

N/A

Enter an ethics statement for this submission. This statement is required if the study involved:

- Human participants
- Human specimens or tissue
- Vertebrate animals or cephalopods
- Vertebrate embryos or tissues
- Field research

Write "N/A" if the submission does not require an ethics statement.

General guidance is provided below. Consult the [submission guidelines](#) for detailed instructions. **Make sure that all information entered here is included in the Methods section of the manuscript.**

**Format for specific study types**

**Human Subject Research (involving human participants and/or tissue)**

- Give the name of the institutional review board or ethics committee that approved the study
- Include the approval number and/or a statement indicating approval of this research
- Indicate the form of consent obtained (written/oral) or the reason that consent was not obtained (e.g. the data were analyzed anonymously)

**Animal Research (involving vertebrate animals, embryos or tissues)**

- Provide the name of the Institutional Animal Care and Use Committee (IACUC) or other relevant ethics board that reviewed the study protocol, and indicate whether they approved this research or granted a formal waiver of ethical approval
- Include an approval number if one was obtained
- If the study involved *non-human primates*, add *additional details* about animal welfare and steps taken to ameliorate suffering
- If anesthesia, euthanasia, or any kind of animal sacrifice is part of the study, include briefly which substances and/or methods were applied

**Field Research**

Include the following details if this study involves the collection of plant, animal, or other materials from a natural setting:

- Field permit number
- Name of the institution or relevant body that granted permission

**Data Availability**

Authors are required to make the data underlying their research findings fully available, without restriction.

If data need to be collected, modified or processed specifically for your study, or if participants need to be recruited specifically for your study, then it should

Yes - any pilot data reported in this submission are fully available and data collected during the study will be made fully available without restriction upon study completion

occur only after your Registered Report Protocol is accepted for publication.

If the manuscript reports pilot results, the data underlying those results should be made available at the time of publication. Submission of this Registered Report Protocol implies a commitment that the data collected in the study, upon completion, will be made available with the Registered Report publication.

When legal or ethical requirements prohibit public data sharing, authors must indicate how researchers may obtain access to the data. See the [PLOS Data Policy](#) and [FAQ](#) for detailed information.

A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and **will be published in the article**, if accepted.

**Important:** Stating 'data available on request from the author' is not sufficient. If your data are only available upon request, select 'No' for the first question and explain your situation in the text box.

Do the authors confirm that all data underlying the findings of the study outlined in this Registered Report Protocol will be made fully available without restriction?

**Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.**

- If no pilot data are reported in the manuscript, please enter the following:  
*All relevant data from this study will be made available upon study completion.*

All relevant data are within the manuscript and its Supporting Information files

- If the manuscript reports pilot data **held in a public repository**, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: *All **XXX** files are available from the **XXX** database (accession number(s) **XXX**, **XXX**).*

- If the manuscript reports pilot data contained **within the manuscript and/or Supporting Information files**, enter the following:

*All relevant data are within the manuscript and its Supporting Information files.*

- If neither of these applies but you are able to provide **details of access elsewhere**, with or without limitations, please do so. For example:

*Data cannot be shared publicly because of **[XXX]**. Data are available from the **XXX** Institutional Data Access / Ethics Committee (contact via **XXX**) for researchers who meet the criteria for access to confidential data.*

*The data underlying the results presented in the study are available from (include the name of the third party and contact information or URL).*

- This text is appropriate if the data are owned by a third party and authors do not have permission to share the data.

\* typeset

Additional data availability information:

# PLOS ONE

## Study Protocol Article Template

1 **Electromyographic parameters for treating pelvic floor disorders in pregnant**  
2 **and postpartum women: A review protocol**

3

4 Alethéa Cury Rabelo Leitão<sup>1#a</sup>, Silvia Oliveira Ribeiro Lira<sup>2#b</sup>, Elizabel de Souza  
5 Ramalho Viana<sup>1#a</sup>

6

7

8 <sup>1</sup> Department of Physical Therapy. Federal University of Rio Grande do Norte, Natal,  
9 Brazil

10 <sup>2</sup> Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Faculdade  
11 de Ciências da Saúde do Trairi (FACISA/UFRN), Santa Cruz, Rio Grande do Norte,  
12 Brazil.

13

14 <sup>#a</sup> Current Address: Department of Physical Therapy. Universidade Federal do Rio  
15 Grande do Norte, Natal, Rio Grande do Norte, Brazil

16 <sup>#b</sup> Current Address: Federal University of Rio Grande do Norte, Natal, Rio Grande do  
17 Norte, Faculdade de Ciências da Saúde do Trairi (FACISA/UFRN), Santa Cruz, Rio  
18 Grande do Norte, Brazil.

19

20 \*Corresponding author

21 E-mail: [ale\\_cury@yahoo.com.br](mailto:ale_cury@yahoo.com.br)

22 These authors contributed equally to this work

### 23 **Author Contributions**

24 **Conceptualization:** Alethéa Cury Rabelo Leitão.

25 **Formal analysis:** Alethéa Cury Rabelo Leitão, Silvia Oliveira Ribeiro

26 Lira.

27 **Investigation:** Alethéa Cury Rabelo Leitão.

28 **Methodology:** Alethéa Cury Rabelo Leitão.

29 **Resources:** Alethéa Cury Rabelo Leitão, Silvia Oliveira Ribeiro

30 Lira.

31 **Supervision:** Elizabel de Souza Ramalho Viana.

32 **Writing – original draft:** Alethéa Cury Rabelo Leitão.

33 **Writing – review & editing:** Alethéa Cury Rabelo Leitão, Elizabel de Souza

34 Ramalho Viana.

35

36

37



## 38 **Abstract**


39 Electromyography is a widely used instrument in clinical practice to evaluate  
40 and treat pelvic floor disorders in pregnant and postpartum women. The objective of  
41 this study is to analyze the scientific evidence on the electromyography parameters  
42 used for treating pelvic floor disorders in pregnant women in any gestational week  
43 and postpartum women up to 12 months after delivery. A systematic review will be  
44 performed in online databases (Scopus, Medline, Pedro, Scielo and Pubmed) of  
45 randomized controlled experimental studies and quasi-experimental studies, in  
46 English, Portuguese or Spanish, which used electromyography as an intervention  
47 for treating pelvic floor disorders in pregnant or post-childbirth women up to 12  
48 months after birth. Risk of bias assessment will be performed using Cochrane group  
49 tools. The Rob 2.0 tool will be used for experimental studies and the Robins-I tool  
50 for non-experimental studies. The protocol was registered in PROSPERO  
51 (nº.433510). The quality of the evidence will be analyzed using the GRADE System  
52 Methodological Guide and the systematic review structure will be performed  
53 according to the Preferred Reporting Items for Systematic Reviews and Meta-  
54 Analyses (PRISMA) guidelines.

55

## 56 **Introduction**

### 57 **Description of the condition**

58 It is consensus that the risk factors for developing pelvic floor disorders in  
59 women are related to the pregnancy and delivery period<sup>(1)</sup>. The pelvic floor of these

60 women will be overloaded during pregnancy due to enlargement of the gravid uterus  
61 from anatomical and physiological changes<sup>(2)</sup>. Therefore, some women may develop  
62 pelvic floor disorders (PFD), such as urinary and fecal incontinence and pelvic organ  
63 prolapse<sup>(3)</sup>. 

64 Perineal, connective tissue, and muscle rupture or weakness may occur after  
65 delivery, which may cause fecal and urinary incontinence, pelvic organ prolapse,  
66 sexual dysfunction, and pain syndromes <sup>(3)</sup>. The literature shows that 50% of women  
67 lose some support functionality of the pelvic floor muscles (PFM) due to childbirth,  
68 and these injuries increase by an average of 20% in women who had vaginal delivery  
69 <sup>(4)</sup>.

70 Pelvic floor muscle training (PFMT) is the first-line treatment for dysfunctions  
71 of this musculature <sup>(5)</sup>. This treatment is based on increasing strength, endurance,  
72 maintaining muscle contraction for a long period of time, muscle coordination,  
73 adherence to and motivation for the training program <sup>(6)</sup>. <sup>(7)</sup>

74 Electromyography can be an adjunct to pelvic floor muscle training for treating  
75 urinary disorders in pregnant and postpartum women.

## 76 **Description of the intervention**

77 There are several methods for evaluating and treating the functionality of the  
78 pelvic floor muscles, such as: digital palpation, manometry, ultrasound,  
79 electromyography and magnetic resonance imaging <sup>(6)</sup><sup>(5)</sup><sup>(8)</sup>

80 A 2021 meta-analysis with more than four thousand women found that the  
81 use of electromyography combined with conservative treatment of the pelvic floor  
82 muscles has better results than the isolated treatment<sup>(1)</sup>

83 Another 2019 meta-analysis with 1,104 studies did not demonstrate that  
84 conservative treatment with electromyographic biofeedback offers a better  
85 intervention alternative for the treatment of this urinary incontinence <sup>(9)</sup>. In other  
86 words, it did not find significant differences in the findings when compared with other  
87 interventions for the same treatment objective<sup>(9)(5)</sup>.

### 88 **How the intervention will work**

89 Electromyography can be used alone or in combination with conservative  
90 treatment. It allows indicating the activity of the pelvic floor muscles in relation to rest  
91 during contraction and during relaxation<sup>(10)(9)</sup>.


92 Clinical studies have evaluated the bioelectric activity of this muscle group  
93 using electromyography<sup>(11)</sup>. This resource has been used as an adjunct to  
94 conservative training and enables the physiotherapist to correctly and objectively  
95 observe the contraction and relaxation of the pelvic floor muscles. Therefore, it  
96 facilitates neuromuscular learning and performs rehabilitation more assertively<sup>(9)(10)</sup>.

97 So far, more recent reviews which analyzed the effectiveness of conservative  
98 treatment with and without electromyography in relation to pelvic floor strength,  
99 urinary incontinence score and quality of sexual life excluded pregnant and  
100 postpartum women from the intervention groups to analyze these effects, leaving  
101 this gap in the literature on this population<sup>(12)(13)(14)</sup>.

102 Knowledge about data on frequency, intensity and type of muscle contraction  
103 can determine goals and therapeutic conduct more assertively. The  
104 electromyographic parameters of the pelvic floor muscles guide the health  
105 professional in choosing the best strategies for the successful treatment of PFM

106 disorders in pregnant and postpartum women. However, due to the scarcity of  
107 studies in this population, a systematic investigation of the literature on the conducts  
108 carried out and their effects so far is necessary.

### 109 **Why is this review important?**

110 It is important to have a better understanding of the electromyography  
111 parameters most used in treating pelvic floor muscle disorders in pregnant and  
112 postpartum women. Identifying electromyography data can be a reference for  
113 elaborating pelvic floor rehabilitation procedures, and thereby contribute to the  
114 prevention and treatment of dysfunctions. Furthermore, previous systematic reviews  
115 have not analyzed the most appropriate therapy for this population when using EMG  
116 alone or in combination in this population. 

117

## 118 **Materials and Methods**

### 119 **Protocol and guidelines**

120 This review will be conducted following the Preferred Reporting Items for  
121 Systematic Reviews and Meta-Analyses (PRISMA) Prisma guidelines<sup>(15)</sup>. The  
122 protocol will be registered with PROSPERO and will be carried out between August  
123 2023 and October 2024.

### 124 **Type of studies**

125 The review will include randomized controlled experimental studies (RCTs)  
126 and non-experimental studies (nRCTs), in English, Portuguese or Spanish, using

127 electromyography in pregnant or postpartum women for evaluating or treating pelvic  
128 floor dysfunctions which analyzed baseline tone, contraction and relaxation capacity.

### 129 **Type of participants**

130 Studies including pregnant women (at any gestational week) and postpartum  
131 women (up to 12 months postpartum) with MAPM who were treated with EMG will  
132 also be considered.

### 133 **Type of interventions**

134 In addition, studies which used electromyography as an instrument, in  
135 isolation or in combination, for evaluating or treating of pelvic floor muscle  
136 dysfunctions that describe the parameters used in the therapy of these women will  
137 also be included.

### 138 **Type of outcome measures**

#### 139 Primary results

- 140 1. Baseline pelvic floor muscle tone
- 141 2. Maximum voluntary contraction of the pelvic floor muscles
- 142 3. Sustained contraction of the pelvic floor muscles
- 143 4. Functionality of the pelvic floor muscles (contraction-relaxation coordination  
144 capacity)
- 145 5. Functionality of the pelvic floor muscles (ability for rapid contractions)

#### 146 Secondary results

- 147 6. Types of electromyographic equipment
- 148 7. Patient positioning during the intervention

149 8. Limitations of the chosen therapy

150 9. Types of Female Pelvic Floor Dysfunction More

151 10. Adverse events

152

153 Electronic database

154 1. Cochrane Central Register of Controlled Trials (CENTRAL)

155 2. MEDLINE (Pubmed)

156 3. Banco de Dados de Evidências em Fisioterapia (PEDro)

157 4. Scopus

158 5. Web of Science

159 6. Scielo

160 7. US National Institutes of Health, Register of Continuous Trials,  
161 ClinicalTrials.gov ([www.clinicaltrials.gov](http://www.clinicaltrials.gov));

162 The strategy on the terms used in each database can be found in Appendix

163 S1.

#### 164 **Searching other resources**

165 Reference checking of primary studies will be done manually and review  
166 articles will be added to the reference.

#### 167 **Selection of studies**

168 Two independent authors (ACRL and SORL) will analyze the articles by titles  
169 and abstracts at the first moment. Eligible studies will be read in full and data  
170 extracted for inclusion. The exclusion reasons for the studies will also be analyzed

171 one by one. Disagreements regarding articles were resolved by a third author by  
172 casting vote (ESRV).

173 Duplicate studies will be identified and excluded. Studies involving men,  
174 children or non-pregnant women will also be excluded from the eligibility process  
175 and detailed in the Guideline Prisma flowchart.


## 176 **Data extraction and management**

177 The authors will extract the characteristics below from the included studies:

- 178 1. Participants: pregnant women in any gestational phase or postpartum women  
179 up to 12 months after delivery, postpartum time, mean age, gestational week,  
180 floor dysfunction for treatment, sample inclusion and exclusion criteria, and  
181 sample description.
- 182 2. Intervention: type of electromyographic equipment, types of electrodes, type  
183 of comparator equipment (if any), use of combined therapy (if any),  
184 intervention time, electromyographic parameters used, description of  
185 alternative interventions (placebo, no intervention or other intervention).
- 186 3. Method: study design, session time, follow-up time, study location, patient  
187 positioning, PFM functionality assessment method, treatment method.
- 188 4. Results: primary and secondary studies that evaluated electromyographic  
189 parameters for treating pelvic floor muscle dysfunctions.
- 190 5. Notes: authors, year of publication, funding of studies, and notable conflicts  
191 of interest among authors

192 Two authors (ACRL and SORL) will perform the initial data extraction from the  
193 included studies after reading the full text and within the inclusion criteria. A

194 “Summary of included studies” table will be created, informing the total number of  
195 studies. In case of disagreements in the extraction of data, a meeting will first be  
196 held for consensus on the extraction, and in the persistence of doubt, a third author  
197 will be deciding by the casting vote (ERSV). The review author (ACRL) will transfer  
198 the summarized data to the Systematic Reviews management program (RevMan  
199 2014) in order to generate the study report and analysis of heterogeneity and the  
200 possibility of meta-analysis of the data.

201 In case of lack of important data to perform the analysis, one of the review  
202 authors will contact you  provide details of the study in question. A professional  
203 fluent in the English language or Google Translator will assist in the translation of  
204 other published languages in case of doubts. The main results will be carefully  
205 reanalyzed by the study authors after translation.

#### 206 **Assesement or risk of bias in the included studies**

207 Two independent authors (ACRL and SORL) will analyze the risk of bias of  
208 experimental studies using the Rob 2.0 tool and for non-experimental studies the  
209 Robins-I tool. Disagreements will be resolved by consensus or involving a third  
210 review author (ESRV).

211 The Rob 2.0 tool is structured in five domains that have “signaling questions”  
212 with the possibility of answers in: “yes”, “probably yes”, “probably not”, “no”, “no  
213 information” and “not applicable”. Definitive “yes” and “no” answers often indicate  
214 that robust evidence is available. The “not applicable” option is only available for  
215 questions with a non-mandatory answer. The final score of the responses



216 determines the risk of bias for each domain: “high risk of bias”, “low risk of bias” or  
217 “unclear”<sup>(16)</sup>

218 The ROBINS-I tool evaluates seven domains of bias, classified by: low risk of  
219 bias, moderate risk of bias, severe risk of bias, critical risk of bias or no information.  
220 The result for the final analysis of each component of the domain is based on the  
221 answers to the guiding questions and tables that support the judgment of bias in  
222 each domain.<sup>(17)</sup>

223 Another bias: the ROBINS-I tool also allows for ranking the overall risk of bias,  
224 which receives the least favorable ranking among the assessed risks for the  
225 assessment tool’s domains.

## 226 **Evidence quality assessment**

227 The evidence quality will be analyzed using the GRADE tool<sup>(18)</sup>. The structure  
228 of the systematic review will follow the recommendation of the Preferred Reporting  
229 Items of Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the  
230 protocol is registered in the PROSPERO database, the international prospective  
231 register of systematic reviews in health and social care  
232 ([www.crd.york.ac.uk/prospero](http://www.crd.york.ac.uk/prospero)).

## 233 **Assessment of bias during the systematic review**

234 The review must be conducted according to this protocol and any adjustments  
235 can be justified in the “Difference between protocol and review” tab in the systematic  
236 review session.

## 237 **Effect treatment measures**

238 Dichotomous data: the odds ratios (ORs) and their associated 95% confidence  
239 intervals (CIs) will be used to determine the value of dichotomous data.

240 Continuous data: will be evaluated using standardized mean differences (STDs) and  
241 their corresponding 95% CIs using the Mantel-Haenzel method.

242 In case of a difference between means, the standard mean can be used for studies  
243 that analyzed the same result using different methods. P-values less than 0.05 will  
244 be considered statistically significant in all cases.

#### 245 **Issues related to a single analysis**

246 Data analyzed in the study may be analyzed using a single analysis on the  
247 outcomes found. Meta-analysis may be used for randomized studies only if the data  
248 are justified for doing so.

#### 249 **Lost data**

250 The authors of the present study will be able to contact the authors of the  
251 articles listed for data analysis in order to resolve doubts or request numerical data  
252 that were not made explicit in the body of the text or which were not found in the  
253 Register of Continuous Tests, ClinicalTrials.gov ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)). There are  
254 cases where only the abstract of the study contains the information, however, in the  
255 course of the text it does not. The failure of contacts and loss of entered data cause  
256 serious bias and this will be considered in the GRADE system.

#### 257 **Evaluation of heterogeneity**

258 If great heterogeneity is identified between the studies, the possible causes  
259 of the data discrepancy can be evaluated using specific sub-groups for analysis. If it  
260 is not possible to analyze the subgroup, the qualitative analysis will be summarized  
261 and presented in tables.

#### 262 **Evaluation of the risk of bias**


263 The funnel chart can investigate reported biases. Symmetry of the funnel plot  
264 can be visually evaluated and explored. 

### 265 **Synthesis of the data**

266 A random effects model and sensitivity analysis with a fixed model can be  
267 used for subgroup analysis and data heterogeneity. It is suggested to follow the  
268 results below for subgroup analysis:

- 269 1. Electromyographic parameters for the treatment of APMD
- 270 2. Limitations of the chosen therapy

271 The following results will be used in subgroup analyzes:

- 272 1. Functionality of the pelvic floor muscles
- 273 2. Most common types of female pelvic floor dysfunction
- 274 3. Adverse events 

275 Statistical analysis for analysis of subgroup interactions will be analyzed using the  
276 Rev-Man tool.

### 277 **Sensitivity analysis**

278 A sensitivity analysis will be conducted to obtain a solid conclusion and to  
279 evaluate the stability of the results. All analyses will be performed using STATA SE  
280 14.0. The sensitivity analysis may explore the influence of the quality of results. This  
281 can be assessed by excluding studies at high risk of bias.

### 282 **Discussion**

283 From an evaluation and analysis of the studies that will be systematically  
284 reviewed, it is intended to analyze the variation of the protocols tested, methods,  
285 terminologies used, as well as definitions of the evaluation of electromyography

286 components of the pelvic floor and their characteristics. In addition, the analysis of  
287 the selected studies on the heterogeneity level of the results is also an objective.  
288 The publication of findings may expose gaps in information about the intervention  
289 and the standardization of interventions, in addition to comparing results and  
290 conclusions between studies.

291 The publication of this protocol will serve as a reference for elaborating  
292 protocols in the rehabilitation of the pelvic floor, identification of the most common  
293 dysfunctions, quality of intervention and outcomes, thus contributing to the care and  
294 monitoring of these pregnant and postpartum women.

295

## 296 **Acknowledgements**

297 None

298

## 299 **References**

- 300 1. Wu X, Zheng X, Yi X, Lai P, Lan Y. Electromyographic Biofeedback for  
301 Stress Urinary Incontinence or Pelvic Floor Dysfunction in Women: A  
302 Systematic Review and Meta-Analysis. *Adv Ther* [Internet].  
303 2021;38(8):4163–77. Available from: [https://doi.org/10.1007/s12325-021-](https://doi.org/10.1007/s12325-021-01831-6)  
304 01831-6
- 305 2. Falah-Hassani K, Reeves J, Shiri R, Hickling D, McLean L. The  
306 pathophysiology of stress urinary incontinence: a systematic review and

- 307 meta-analysis. *Int Urogynecol J*. 2021;32(3):501–52.
- 308 3. Mørkved S, Bø K. Effect of pelvic floor muscle training during pregnancy and  
309 after childbirth on prevention and treatment of urinary incontinence: A  
310 systematic review. *Br J Sports Med*. 2014;48(4):299–310.
- 311 4. Caetano AS, Gomes C, Fernandes C, Baena H, Lopes DM. Incontinência  
312 urinária e a prática de atividades físicas. *Rev Bras Med Esporte*.  
313 2007;13(4):270–4.
- 314 5. Mateus-Vasconcelos ECL, Ribeiro AM, Antônio FI, Brito LG de O, Ferreira  
315 CHJ. Physiotherapy methods to facilitate pelvic floor muscle contraction: A  
316 systematic review. *Physiother Theory Pract* [Internet]. 2018;34(6):420–32.  
317 Available from: <https://doi.org/10.1080/09593985.2017.1419520>
- 318 6. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus  
319 no treatment, or inactive control treatments, for urinary incontinence in  
320 women. *Cochrane Database Syst Rev*. 2018;2018(10):2–186.
- 321 7. Paula A, Resende M, Nakamura MU, Alves E, Ferreira G, Petricelli CD, et al.  
322 Eletromiografia de superfície para avaliação dos músculos do assoalho  
323 pélvico feminino : revisão de literatura. 2011;18(3):292–7.
- 324 8. Marques J, Botelho S, LC P, AH L, CF A, Palma P, et al. Pelvic floor muscle  
325 training program increases muscular contractility during first pregnancy and  
326 postpartum: electromyographic study. [Internet]. Vol. 32, *Neurourology and*  
327 *urodynamics*. United States; 2013. p. 998–1003. Available from:

- 328 <https://pubmed.ncbi.nlm.nih.gov/23129397/>
- 329 9. Nunes EFC, Sampaio LMM, Biasotto-Gonzalez DA, Nagano RC dos R,  
330 Lucareli PRG, Politti F. Biofeedback for pelvic floor muscle training in women  
331 with stress urinary incontinence: a systematic review with meta-analysis.  
332 *Physiother (United Kingdom)* [Internet]. 2019;105(1):10–23. Available from:  
333 <https://doi.org/10.1016/j.physio.2018.07.012>
- 334 10. Koenig I, Luginbuehl H, Radlinger L. Reliability of pelvic floor muscle  
335 electromyography tested on healthy women and women with pelvic floor  
336 muscle dysfunction. *Ann Phys Rehabil Med* [Internet]. 2017;60(6):382–6.  
337 Available from: <http://dx.doi.org/10.1016/j.rehab.2017.04.002>
- 338 11. Koh CE, Young CJ, Young JM, Solomon MJ. Systematic review of  
339 randomized controlled trials of the effectiveness of biofeedback for pelvic  
340 floor dysfunction. *Br J Surg*. 2008;95(9):1079–87.
- 341 12. Fernandes ACNL, Palacios-Ceña D, Pena CC, Duarte TB, de la Ossa AMP,  
342 Jorge CH. Conservative non-pharmacological interventions in women with  
343 pelvic floor dysfunction: a systematic review of qualitative studies. *BMC*  
344 *Womens Health* [Internet]. 2022;22(1). Available from:  
345 <https://doi.org/10.1186/s12905-022-02097-y>
- 346 13. Moroni R, Magnani P, Haddad J, Castro R, Brito L. Conservative Treatment  
347 of Stress Urinary Incontinence: A Systematic Review with Meta-analysis of  
348 Randomized Controlled Trials. *Rev Bras Ginecol e Obs / RBGO Gynecol*

349 Obstet. 2016;38(02):097–111.

350 14. López-Liria R, Varverde-Martínez MDLÁ, Padilla-Góngora D, Rocamora-  
351 Pérez P. Effectiveness of physiotherapy treatment for urinary incontinence in  
352 women: A systematic review. *J Women's Heal.* 2019;28(4):490–501.

353 15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,  
354 et al. The PRISMA 2020 statement: An updated guideline for reporting  
355 systematic reviews. *BMJ.* 2021;372.

356 16. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al.  
357 RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ.*  
358 2019;366:1–8.

359 17. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan  
360 M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised  
361 studies of interventions. *BMJ.* 2016;355:4–10.

362 18. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et  
363 al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol.*  
364 2011;64(4):401–6.

365

## 366 **Supporting information**

367 S1 Checklist. PRISMA-P (Preferred Reporting Items for Systematic review and

368 Meta

369 Analysis Protocols) 2015 checklist: Recommended items to address in a  
370 systematic review protocol.(DOC)

371 S1 Appendix.(DOCX)

372






Click here to access/download

**Supporting Information**

3. Supporting Information (Prisma-P).docx





Click here to access/download  
**Supporting Information**  
4. S1 Appendix.docx

